Hepatect Cp (Human Hepatitis B Immunoglobulin)

Hepatect Cp is a prescription intravenous injection containing human hepatitis B immunoglobulin as its active ingredient. It is supplied in a sterile solution (strength not specified) and is intended for passive immunization against hepatitis B virus. The product is marketed in the European Union and belongs to the immunoglobulin drug class, classified under antiviral therapeutic class (ATC code J06BA02). It is administered and stored according to label instructions.

Hepatect Cp is indicated for several clinical situations where passive immunity against hepatitis B virus is required.

- Post‑exposure prophylaxis for individuals who have been exposed to hepatitis B virus. - Prevention of hepatitis B recurrence in patients undergoing liver transplantation. - Prophylaxis of hepatitis B infection in newborns born to HBsAg‑positive mothers. - Supplementation of hepatitis B immunity in patients with inadequate vaccine response. - Use in combination with hepatitis B vaccine for enhanced protection in high‑risk populations.

Adverse reactions to Hepatect Cp are generally related to the intravenous administration of human immunoglobulin and may vary in frequency and severity.

Common: - Mild fever or chills during or shortly after infusion. - Headache or fatigue. - Nausea, vomiting, or abdominal discomfort. - Localized infusion site reactions such as erythema or swelling. - Transient hypotension or dizziness.

Serious: - Allergic reactions including urticaria, angioedema, or anaphylaxis. - Acute hemolytic transfusion reactions. - Renal impairment or acute kidney injury. - Thrombotic events such as deep vein thrombosis.

When prescribing Hepatect Cp, clinicians should consider patient-specific factors and follow safety guidelines to minimize risks associated with immunoglobulin therapy.

- Assess for known hypersensitivity to human immunoglobulin or any product components. - Evaluate renal function before infusion, especially in patients with pre‑existing kidney disease. - Monitor for signs of hemolysis in individuals with blood group incompatibilities. - Use caution in patients with a history of thromboembolic disorders. - Avoid rapid infusion rates; adhere to recommended administration speed. - Consider pregnancy status; data are limited, and benefits should outweigh potential risks.

Hepatect Cp may interact with other medications or clinical conditions; awareness of potential interactions helps ensure safe administration.

Avoid: - Concurrent use of other blood products containing anti‑HBs antibodies without medical justification. - Administration with live vaccines during the same visit, as passive antibodies may reduce vaccine efficacy.

Use with caution: - Concomitant anticoagulants or antiplatelet agents, due to possible increased bleeding risk. - Immunosuppressive therapies, which may alter the immunogenic response. - Renal‑impairing drugs, requiring close monitoring of kidney function. - High‑dose steroids, which could affect infusion tolerance.